Ozempic, Wegovy, Other Glp-1ra Drugs Not Linked To Increased Pancreatic Cancer Risk, Study Finds

Are Ozempic, Wegovy, and other GLP-1 receptor agonists linked to pancreatic cancer risk?Recent studies have examined whether GLP-1 receptor agonists (GLP-1RAs), including semaglutide (Ozempic, Wegovy), increase pancreatic cancer risk. In this episode, we review the current evidence and how medication safety is assessed in Europe.In this episode, we cover:• What GLP-1 receptor agonists are and how they work• Why pancreatic safety concerns were previously raised• Findings from recent large observational studies• The difference between association and causation• Ongoing pharmacovigilance and regulatory monitoring in the EU• Known side effects of GLP-1 medicines• Who may not be suitable candidates for GLP-1 therapy• Situations where prescription requests may be declinedDoctors assess diabetes status, BMI, personal and family history of pancreatitis or pancreatic disease, gallbladder history, kidney function, and concurrent medications before prescribing. GLP-1 medicines are not appropriate for everyone, and some patients require blood tests or in-person review prior to initiation.This episode reflects how medication safety and metabolic treatment decisions are reviewed within European telemedicine at Mobi Doctor.Read the full medical guide here:https://www.mobidoctor.eu/blog/ozempic-wegovy-other-glp-1ra-drugs-not-linked-to-increased-pancreatic-cancer-risk-study-finds